PHARMING GROUP NV - ADR (PHAR) Stock Fundamental Analysis
NASDAQ:PHAR - Nasdaq - US71716E1055 - ADR - Currency: USD
PHAR gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. Both the profitability and the financial health of PHAR get a neutral evaluation. Nothing too spectacular is happening here. PHAR is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PHAR had negative earnings in the past year.
PHAR had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PHAR reported negative net income in multiple years.
In multiple years PHAR reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -3.50%, PHAR belongs to the top of the industry, outperforming 88.26% of the companies in the same industry.
Looking at the Return On Equity, with a value of -6.59%, PHAR belongs to the top of the industry, outperforming 89.32% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 2.05%, PHAR belongs to the top of the industry, outperforming 92.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.5% | ||
| ROE | -6.59% | ||
| ROIC | 2.05% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 2.63%, PHAR belongs to the top of the industry, outperforming 92.53% of the companies in the same industry.
PHAR has a better Gross Margin (88.98%) than 91.46% of its industry peers.
PHAR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.63% | ||
| PM (TTM) | N/A | ||
| GM | 88.98% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
2. Health
2.1 Basic Checks
PHAR has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for PHAR has been increased compared to 1 year ago.
The number of shares outstanding for PHAR has been increased compared to 5 years ago.
PHAR has a better debt/assets ratio than last year.
2.2 Solvency
PHAR has an Altman-Z score of 2.45. This is not the best score and indicates that PHAR is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.45, PHAR is in the better half of the industry, outperforming 72.06% of the companies in the same industry.
PHAR has a debt to FCF ratio of 23.45. This is a negative value and a sign of low solvency as PHAR would need 23.45 years to pay back of all of its debts.
PHAR's Debt to FCF ratio of 23.45 is amongst the best of the industry. PHAR outperforms 91.28% of its industry peers.
A Debt/Equity ratio of 0.52 indicates that PHAR is somewhat dependend on debt financing.
PHAR has a Debt to Equity ratio of 0.52. This is in the lower half of the industry: PHAR underperforms 73.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 23.45 | ||
| Altman-Z | 2.45 |
ROIC/WACC0.3
WACC6.94%
2.3 Liquidity
PHAR has a Current Ratio of 2.76. This indicates that PHAR is financially healthy and has no problem in meeting its short term obligations.
PHAR has a Current ratio of 2.76. This is in the lower half of the industry: PHAR underperforms 66.55% of its industry peers.
A Quick Ratio of 2.00 indicates that PHAR should not have too much problems paying its short term obligations.
PHAR has a Quick ratio of 2.00. This is in the lower half of the industry: PHAR underperforms 73.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.76 | ||
| Quick Ratio | 2 |
3. Growth
3.1 Past
The earnings per share for PHAR have decreased strongly by -50.00% in the last year.
Looking at the last year, PHAR shows a very strong growth in Revenue. The Revenue has grown by 24.13%.
PHAR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.64% yearly.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.79%
Revenue 1Y (TTM)24.13%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%42.29%
3.2 Future
The Earnings Per Share is expected to grow by 52.28% on average over the next years. This is a very strong growth
PHAR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.99% yearly.
EPS Next Y183.09%
EPS Next 2Y10.31%
EPS Next 3Y46.06%
EPS Next 5Y52.28%
Revenue Next Year14.32%
Revenue Next 2Y10.95%
Revenue Next 3Y10.23%
Revenue Next 5Y9.99%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PHAR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHAR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
93.06% of the companies in the same industry are more expensive than PHAR, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHAR indicates a rather cheap valuation: PHAR is cheaper than 91.64% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 134.63 | ||
| EV/EBITDA | 30.63 |
4.3 Compensation for Growth
A more expensive valuation may be justified as PHAR's earnings are expected to grow with 46.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.31%
EPS Next 3Y46.06%
5. Dividend
5.1 Amount
No dividends for PHAR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10
-0.01 (-0.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners10.96%
Inst Owner Change0%
Ins Owners1.41%
Ins Owner ChangeN/A
Market Cap683.93M
Analysts88.57
Price Target17.13 (71.3%)
Short Float %0%
Short Ratio0.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-34.81%
Min EPS beat(2)-42.39%
Max EPS beat(2)-27.22%
EPS beat(4)1
Avg EPS beat(4)-61.09%
Min EPS beat(4)-197.09%
Max EPS beat(4)22.33%
EPS beat(8)3
Avg EPS beat(8)-66.01%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)12.4%
Min Revenue beat(2)11.43%
Max Revenue beat(2)13.37%
Revenue beat(4)2
Avg Revenue beat(4)3.98%
Min Revenue beat(4)-5.54%
Max Revenue beat(4)13.37%
Revenue beat(8)5
Avg Revenue beat(8)1.21%
Revenue beat(12)5
Avg Revenue beat(12)-2.03%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.9%
PT rev (3m)12.32%
EPS NQ rev (1m)-233.33%
EPS NQ rev (3m)-227.56%
EPS NY rev (1m)0%
EPS NY rev (3m)155.14%
Revenue NQ rev (1m)4.67%
Revenue NQ rev (3m)4.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.13 | ||
| P/FCF | 134.63 | ||
| P/OCF | 112.41 | ||
| P/B | 3.2 | ||
| P/tB | 9.1 | ||
| EV/EBITDA | 30.63 |
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)0.07
FCFY0.74%
OCF(TTM)0.09
OCFY0.89%
SpS4.69
BVpS3.13
TBVpS1.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.5% | ||
| ROE | -6.59% | ||
| ROCE | 2.59% | ||
| ROIC | 2.05% | ||
| ROICexc | 3.06% | ||
| ROICexgc | 8.39% | ||
| OM | 2.63% | ||
| PM (TTM) | N/A | ||
| GM | 88.98% | ||
| FCFM | 1.58% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score5
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 23.45 | ||
| Debt/EBITDA | 5.21 | ||
| Cap/Depr | 7.89% | ||
| Cap/Sales | 0.31% | ||
| Interest Coverage | 2.2 | ||
| Cash Conversion | 28.73% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.76 | ||
| Quick Ratio | 2 | ||
| Altman-Z | 2.45 |
F-Score5
WACC6.94%
ROIC/WACC0.3
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.79%
EPS Next Y183.09%
EPS Next 2Y10.31%
EPS Next 3Y46.06%
EPS Next 5Y52.28%
Revenue 1Y (TTM)24.13%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%42.29%
Revenue Next Year14.32%
Revenue Next 2Y10.95%
Revenue Next 3Y10.23%
Revenue Next 5Y9.99%
EBIT growth 1Y128.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.21%
EBIT Next 3Y76.77%
EBIT Next 5Y85.48%
FCF growth 1Y284.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y750%
OCF growth 3YN/A
OCF growth 5YN/A